skip to Global Navigation Bar skip to main content

homeHome > About Us > Press Release > News


News Content
Daewoong Pharmaceutical’s Nabota, Exposed latest clinical study result and treatment regimen at IMCAS ASIA 2018
Date 2018-07-18 Hit 1446
News List
Prev Daewoong Pharmaceutical successfully held ‘NABOTA SEOUL 2018’
Next Daewoong Pharmaceutical’s ‘NABOTA’ becomes the first Korea-made Botulinum Toxin to obtain US FDA approval